1. Basic and Applied Immunology Program, Ribeirão Preto Medical School,
2. Center for Cell-based Therapy, Regional Hemotherapy Center of the Ribeirão Preto Medical School,
3. Department of Clinical, Toxicological and Bromatological Analysis, School of Pharmaceutical Sciences of Ribeirão Preto, and
4. Graduate Program on Bioscience Applied to Pharmacy, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil;
5. INSERM Unité Mixte de Recherche 1160, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France;
6. Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France;
7. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil;
8. Plateforme Technologique, Institut Universitaire d'Hématologie, Paris, France; and
9. Unité de Médecine Interne, Maladies Autoimmunes et Pathologie Vasculaire, UF 04, AP-HP, Centre de référence des maladies auto-immunes systémiques rares d’Ile-de-France (site constitutif), FAI2R, Hôpital Saint-Louis, Paris, France